Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“Follow MedCity News if you want to know who is doing what in healthcare innovation - and whether it's working or not.”

Chris Seper, CEO & Founder, MedCityNews.com


Sign up for our daily newsletter


InteraXon snags $6M to further develop Muse ‘brain-sensing’ headband

2:59 pm by | 0 Comments

Interaxon_Muse

VANCOUVER — CEO Ariel Garten announced the news at the Grow Conference in Vancouver, where she demoed the company’s product, the Muse, which has six sensors that replace a traditional head-covering EEG machine in a single slim, attractive headband.

“Muse is the brain-sensing headband that allows you to track your cognitive and emotional activity,” Garten told me after her speech. “It boosts your attention and helps you become more aware of the emotions that you’re having.”

InteraXon started with a successful Indiegogo campaign that raised almost $300,000 and funded the company’s first production series, Garten said. Now the company has followed up that crowdsourcing success with a very healthy series A. Investors include OMERS, Ashton Kutcher’s investment company, and FFEC, which led the initial seed round in InteraXon.

The headband allows you to “control games, reduce stress, improve memory and concentration,” Interaxon says. Eventually, you’ll be able to control devices around you, and perhaps things like home automation, simply by thinking.

Advertisement

Right now, the money is going to improve the company’s technology, and to build its market.

“We’re going to use this money to get more devices into the market,” Garten told me. “We’ll also build out our team, and build better algorithms.”

This article originally appeared on VentureBeat

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

By John Koetsier,

Visit website | More posts by Author

0 comments

Hear the latest news first

Get our daily newsletter or follow us.

 

Advertisement